Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00206050 |
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Esomeprazole Drug: pantoprazole |
Phase IV |
Study Type: | Interventional |
Study Design: | Educational/Counseling/Training, Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study |
Official Title: | A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-Hour Intragastric pH Profile After 5 Days of Once Daily Oral Administration of Either Esomeprazole 40 Mg or Pantoprazole 40 Mg Following Once Daily Infusion of Intravenous Pantoprazole 40 Mg for 5 Days in Healthy Volunteer Subjects |
Estimated Enrollment: | 40 |
Study Start Date: | October 2004 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | D9612L00066 |
Study First Received: | September 12, 2005 |
Last Updated: | September 20, 2005 |
ClinicalTrials.gov Identifier: | NCT00206050 |
Health Authority: | United States: Food and Drug Administration |
Pantoprazole Omeprazole Healthy |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |